Lothian NHS Board

Waverley Court
4 East Market Street
Edinburgh
EH8 8BG

Telephone: 0131 536 9000
www.nhslothian.scot.nhs.uk

Date: 16/11/2026
Our Ref: 12045
Enquiries to loth.freedomofinfomation@nhs.scot

Dear

FREEDOM OF INFORMATION – CANCER TREATMENT

I write in response to your request for information in relation to cancer treatment in NHS Lothian.

Question:

1. How many patients were treated with SACT therapy only, as opposed to radiotherapy or surgery, for the following types of cancer? Please count for the 12 months between 1st October 2025 and the end of September 2026, or latest 12-months for which data are available.

1.1 Colorectal Cancer
1.2 Colon Cancer

Answer:

The information you have requested is detailed in the table below: Please note that colon cancer is a subset of colorectal.

SACT therapy, latest 12 months, NHS Lothian	
Therapy area	**Number of patients**
Colorectal Cancer	359
Colon Cancer	257

Question:

2. How many patients were treated with SACT therapy only, as opposed to radiotherapy or surgery, for the following types of cancer? Please count for the 3 months between 1st July 2026 and the end of September 2026, or latest 3-months for which data are available.

2.1 Colorectal Cancer
2.2 Colon Cancer

Answer:

The information you have requested is detailed in the table below: Please note that colon cancer is a subset of colorectal.

SACT therapy, latest 3 months, NHS Lothian	
Therapy area	**Number of patients**
Colorectal Cancer	187
Colon Cancer	134

Question:

3. How many patients with the following types of cancer were treated with surgical resection in the past 3 months from 1st July 2026 to the end of September 2026?

3.1 Colorectal Cancer
3.2 Colon Cancer

Answer:

This information is not collected centrally. This is because the diagnosis is not linked to surgical treatment in our electronic patient management system. Information will be held in individual patient records, but in order to provide the information you request it would be necessary to review each patient record over the period you have specified, requiring significant resources. Under section 12 of the Freedom of Information (Scotland) Act 2002, NHS Lothian is not required to respond to your request if the resources required to do so equate to more than £600 in cost.

Question:

4. How many patients with the following types of cancer received SACT therapy as Adjuvant treatment in the past 3 months from 1st July 2026 to the end of September 2026?

4.1 Colorectal Cancer
4.2 Colon Cancer

Answer:

The information you have requested is detailed in the table below: Please note that colon cancer is a subset of colorectal.

SACT therapy as adjuvant treatment, latest 3 months, NHS Lothian	
Therapy area	**Number of patients**
Colorectal Cancer	49
Colon Cancer	36

Question:

5. How many patients with Colorectal Cancer (ICD-10 C18*, C19* & C20*) received these treatment combinations as adjuvant therapy in the past 3 months from 1st July 2026 to the end of September 2026?

5.1 FOLFOX - Fluorouracil + Folinic Acid + Oxaliplatin

5.2 XELOX - Capecitabine + Oxaliplatin
5.3 FOLFIRI - Fluorouracil + Folinic Acid + Irinotecan
5.4 XELIRI Capecitabine + Irinotecan
5.5 Nivolumab + Ipilimumab

Answer:

The information you have requested is detailed in the table below:

Combinations as adjuvant therapy for Colorectal Cancer, latest 3 months, NHS Lothian Treatment combination	Number of patients
5.1 FOLFOX - Fluorouracil + Folinic Acid + Oxaliplatin	0
5.2 XELOX - Capecitabine + Oxaliplatin	0
5.3 FOLFIRI - Fluorouracil + Folinic Acid + Irinotecan	0
5.4 XELIRI Capecitabine + Irinotecan	0
5.5 Nivolumab + Ipilimumab	0

Question:

6. How many patients with Colon Cancer (ICD-10 C18*) received these treatment combinations as adjuvant therapy in the past 3 months from 1st July 2026 to the end of September 2026?

6.1 FOLFOX - Fluorouracil + Folinic Acid + Oxaliplatin
6.2 XELOX - Capecitabine + Oxaliplatin
6.3 FOLFIRI - Fluorouracil + Folinic Acid + Irinotecan
6.4 XELIRI Capecitabine + Irinotecan
6.5 Nivolumab + Ipilimumab

Answer:

The information you have requested is detailed in the table below:

Combinations as adjuvant therapy for Colon cancer, latest 3 months, NHS Lothian Treatment combination	Number of patients
5.1 FOLFOX - Fluorouracil + Folinic Acid + Oxaliplatin	0
5.2 XELOX - Capecitabine + Oxaliplatin	0
5.3 FOLFIRI - Fluorouracil + Folinic Acid + Irinotecan	0
5.4 XELIRI Capecitabine + Irinotecan	0
5.5 Nivolumab + Ipilimumab	0

Question:

7. How many patients were treated with cemiplimab (Libtayo) for the following types of cancer in the 3 months between 1st July 2026 to the end of September 2026, or latest 3-months for which data are available?

7.1 Cutaneous Squamous Cell Carcinoma
7.2 Basal Cell Carcinoma
7.3 Non-small Cell Lung Cancer
7.4 Cervical Cancer

Answer:

The information you have requested is detailed in the table below:

Patients treated with cemiplimab (Libtayo), latest 3 months, NHS Lothian	
Tumour type	**Number of patients**
7.1 Cutaneous Squamous Cell Carcinoma	15
7.2 Basal Cell Carcinoma	Information not held
7.3 Non-small Cell Lung Cancer	0
7.4 Cervical Cancer	0

Question:

8. How many patients treated with cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma were treated with the following treatment intent in the 3 months between 1st July 2026 to the end of September 2026, or latest 3-months for which data are available?

8.1 Curative
8.2 Palliative

Answer:

The information you have requested is detailed in the table below:

Patients treated with cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma, latest 3 months, NHS Lothian	
Treatment intent	**Number of patients**
8.1 Curative	0
8.2 Palliative	15

Question:

9. How many patients received cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma as adjuvant treatment in the 3 months between 1st July 2026 to the end of September 2026, or latest 3-months for which data are available?

9.1 Adjuvant

Answer:

0 patients received cemiplimab (Libtayo) for Cutaneous Squamous Cell Carcinoma as an adjuvant treatment during this period.

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at https://www.foi.scot/appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the reviewer at the address at the top of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: https://org.nhslothian.scot/FOI

Yours sincerely

ALISON MACDONALD
Executive Director of Nursing Midwifery and AHPs
Cc: Chief Executive